Replies to post #71872 on Ayala Pharmaceuticals Inc (ADXS)

[DewDiligence]

AMGN has primary responsibility for NEO following proof-of-concept:

https://www.sec.gov/Archives/edgar/data/1100397/000149315217000250/ex10-57.htm (p.16):

Following the Early Development Term*, Amgen shall have primary responsibility for overseeing all development activities for the Products (including sponsorship and conduct of any Phase 3 Clinical Trial of Products).

Notwithstanding the foregoing, Amgen shall consult with, and consider in good faith any input provided by, Advaxis regarding any material plans or decisions regarding the development of Products following the Early Development Term. Following the Early Development Term, Amgen shall bear all costs associated with development activities relating to Products.

* “Early Development Term” means the period from the Effective Date [of the NEO collaboration] until the POC Date.